Form 4: Catalyst Pharma Officer Boosts Stake, Receives New Equity

Catalyst Pharmaceuticals' Chief Operating & Scientific Officer, Steve Miller, reported the acquisition of common stock and new equity awards, increasing his beneficial ownership.

Summary

• Steve Miller, Chief Operating & Scientific Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported several equity transactions.
• Acquired 8,267 shares of common stock on November 21, 2025, through the vesting of restricted stock units.
• Received a grant of 158,454 options to purchase common stock on November 20, 2025, with an exercise price of $22.77.
• Received a grant of 47,826 Restricted Stock Units (RSUs) on November 20, 2025.
• Following these transactions, Miller directly owns 1,067,930 shares of common stock.
• He also beneficially owns 1,457,963 options and 1,497,522 Restricted Stock Units.

Sentiment

Score: 7

Explanation: The Chief Operating & Scientific Officer acquired common stock through vesting and received substantial new equity awards (options and RSUs), which generally signals management's confidence in the company's future prospects and aligns their interests with shareholders.

Positives

• Increased direct ownership of common stock by a key executive, signaling confidence in the company's future.
• Grant of significant new equity awards (options and RSUs) aligns management's long-term interests with shareholders.

Negatives

• No explicit negatives reported in this Form 4 filing.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

The reporting person's future beneficial ownership of common stock is expected to increase as additional tranches of options and restricted stock units vest on November 20, 2026, November 21, 2026, November 20, 2027, November 21, 2027, and November 20, 2028.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology and pharmaceutical industry, where equity awards like stock options and restricted stock units are commonly used to incentivize and retain key management personnel, aligning their long-term interests with company performance.

Stakeholder Impact

• Shareholders: Increased alignment of management's interests with shareholders due to higher equity ownership. Potential minor dilution from future share issuance upon vesting/exercise of awards.
• Employees: May signal stability and confidence in the company's leadership.

Next Steps

• Future vesting of 158,454 options in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028.
• Future vesting of 47,826 Restricted Stock Units in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028.
• Future vesting of the remaining 16,534 Restricted Stock Units from the 11/21/2025 grant in two equal tranches on November 21, 2026, and November 21, 2027.

Key Dates

Keywords

Catalyst Pharmaceuticals, CPRX, Steve Miller, Insider Transaction, Form 4, Stock Options, Restricted Stock Units, Equity Awards, Beneficial Ownership, Officer Compensation